Surplus chemical inventory can be transformed from a costly operational challenge (storage, disposal, environmental liabilities) into a profitable asset and a key driver for sustainability.
Sur+ specializes in this process by connecting manufacturing companies in North America and Europe with a global network of buyers, with a strong focus on markets like India and the Far East.
The core value proposition is:
The process is designed to be seamless and cost-free for the seller. Provide inventory details (stock lists, Safety Data Sheets, Certificates of Analysis), receive a competitive offer, and Sur+ manages and covers all secure logistics and transportation. Strict confidentiality protocols are guaranteed at every stage.
Sur+ acquires a broad range of materials, including Solvents, Polymers, and Specialty Chemicals.
While the primary market for newly produced titanium dioxide is vast, a significant and often overlooked segment offers immense strategic value: the trading of surplus, off-spec, or discontinued TiO2. This niche, where Sur+ specializes, presents a world of solutions for surplus stock, transforming what might otherwise be waste into a valuable resource. We empower manufacturing companies across North America and Europe to unlock economic value from their excess inventory, while simultaneously providing cost-effective, high-quality materials to buyers, particularly in developing countries, India, and the Far East. Our mission integrates sustainability into every solution we provide, driving both economic efficiency and environmental responsibility.
We recognize that one company’s surplus or off-spec material can be another’s ideal, cost-effective raw material. At Sur+, we bridge the gap between supply and demand, integrating sustainability into every solution we provide.
The pharmaceutical supply chain is at a crossroads. The old model of siloed operations and transactional relationships is no longer fit for purpose. The future belongs to a new model of radical collaboration, where specialized partners work together to create a more resilient, efficient, and sustainable ecosystem. This article explores how innovative partnerships in surplus management are transforming the supply chain, reducing waste, and unlocking new value. Discover the lessons that will be shared at CPHI India 2025 and how you can be part of building tomorrow’s pharmaceutical supply chain.
India’s pharmaceutical sector, the “pharmacy of the world,” is facing a critical challenge: a staggering 651 tonnes of biomedical waste generated daily. This article explores the unique complexities of India’s pharmaceutical surplus problem, from the stringent “red category” regulations to the hidden operational costs. Discover how leading companies are turning this challenge into a multi-billion dollar opportunity by embracing circular economy principles, transforming compliance costs into revenue streams, and securing a competitive edge in the global market.
The global chemical industry is at a pivotal juncture, navigating a complex interplay of shifting trade policies, stringent new regulations, and persistent economic headwinds. For international chemical traders, particularly those operating in the critical Europe-US corridor, the landscape is evolving at an unprecedented pace. The past month alone has brought a series of developments that will have far-reaching implications for supply chains, market access, and competitive positioning. This article provides a comprehensive analysis of these recent trends, offering insights and practical recommendations for industry leaders to navigate this dynamic environment successfully. We will delve into the nuances of the new US-EU trade framework, the challenges confronting the European chemical sector, the evolving regulatory landscape, and the transformative potential of technology and automation. By understanding these interconnected forces, chemical trading companies can not only mitigate risks but also identify and seize emerging opportunities for growth and innovation.
Copyright © 2024 | Powered by Surplus Inter
